MCID: HYP063
MIFTS: 53

Hypersplenism

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Hypersplenism

MalaCards integrated aliases for Hypersplenism:

Name: Hypersplenism 12 54 43 15 17 71 32
Hypersplenia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6376
ICD9CM 34 289.4
MeSH 43 D006971
NCIt 49 C34714
SNOMED-CT 67 58381000
ICD10 32 D73.1
UMLS 71 C0020532

Summaries for Hypersplenism

MalaCards based summary : Hypersplenism, also known as hypersplenia, is related to anemia, x-linked, with or without neutropenia and/or platelet abnormalities and esophageal varix. An important gene associated with Hypersplenism is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Tacrolimus and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and bone, and related phenotypes are immune system and hematopoietic system

Wikipedia : 74 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Hypersplenism

Diseases related to Hypersplenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 570)
# Related Disease Score Top Affiliating Genes
1 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 31.0 FOXP3 EPO CSF3 ALB
2 esophageal varix 30.9 SERPINC1 GPT F2 ALB
3 splenic abscess 30.8 GPT F2 ALB
4 ileus 30.7 IFNG F2 CSF2
5 sickle cell anemia 30.7 F2 EPO CSF3 ALB
6 hemolytic anemia 30.6 IL4 IFNG F2 EPO CSF3
7 splenic infarction 30.6 SERPINC1 GPT F2 ALB
8 liver cirrhosis 30.4 THPO SERPINC1 GPT F2 ALB
9 paralytic ileus 30.4 GPT F2 ALB
10 endocarditis 30.3 SERPINC1 IFNG F2 ALB
11 q fever 30.3 TLR4 IL4 IFNG
12 mycobacterium tuberculosis 1 30.3 TLR4 IL4 IFNG CD4
13 sarcoidosis 1 30.3 LTA IL2RA IFNG CD4
14 portal hypertension 30.2 TLR4 THPO GPT F2 CD4 ALB
15 hepatoportal sclerosis 30.2 GPT F2
16 paroxysmal nocturnal hemoglobinuria 30.2 SERPINC1 F2 CSF3
17 schistosomiasis 30.2 IL4 IFNG GPT F2 ALB
18 biliary atresia 30.1 IFNG GPT F2 ALB
19 peripheral vascular disease 30.1 SERPINC1 F2 EPO ALB
20 splenic sequestration 30.1 THPO F2 EPO CD4
21 hepatic encephalopathy 30.1 GPT F2 ALB
22 brucellosis 30.1 TLR4 IL4 IFNG
23 hepatic coma 30.1 SERPINC1 GPT F2 ALB
24 hepatorenal syndrome 30.0 GPT F2 ALB
25 peritonitis 30.0 TLR4 IL4 IFNG F2 CSF3 ALB
26 deficiency anemia 29.9 THPO SERPINC1 EPO BMP6 ALB
27 candidiasis 29.9 TLR4 IL4 IFNG CSF2
28 bilirubin metabolic disorder 29.9 GPT F2 ALB
29 aphthous stomatitis 29.9 TLR4 IL4 IFNG CSF2
30 purpura 29.9 THPO SERPINC1 IL4 IFNG F2
31 duodenal ulcer 29.8 TLR4 LTA EGF
32 thymoma 29.8 IL4 FOXP3 EGF CSF3
33 bacterial infectious disease 29.8 TLR4 IFNG CSF3 CSF2 CD4
34 dysentery 29.8 TLR4 GPT CD4 ALB
35 thrombocytopenia due to platelet alloimmunization 29.7 THPO FOXP3 CD4
36 hepatitis b 29.7 TLR4 IFNG GPT F2 ALB
37 toxic shock syndrome 29.6 TLR4 SERPINC1 LTA IL4 IFNG
38 abdominal tuberculosis 29.6 IFNG GPT F2 CD4 ALB
39 syphilis 29.6 IFNG GPT F2 CD4 ALB
40 acquired immunodeficiency syndrome 29.5 IL2RA IFNG EPO CSF2 CD4 ALB
41 mycosis fungoides 29.5 IL4 IL2RA IFNG FOXP3
42 stomatitis 29.4 TLR4 IL4 IFNG CSF3 CSF2 CD4
43 autoimmune hepatitis 29.4 IL4 GPT FOXP3 F2 ALB
44 lymphoma 29.3 REL LTA IL4 IL2RA CSF3 CSF2
45 visceral leishmaniasis 29.3 TLR4 LTA IL4 IFNG FOXP3 ALB
46 cholecystitis 29.3 TLR4 GPT F2 EGF ALB
47 myeloproliferative neoplasm 29.2 THPO EPO CSF3 CSF2
48 hemoglobinuria 29.2 THPO SERPINC1 F2 EPO CSF3
49 viral hepatitis 29.2 TLR4 IL4 IFNG GPT F2 ALB
50 heart disease 29.2 TLR4 SERPINC1 GPT F2 EPO CD4

Comorbidity relations with Hypersplenism via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Deficiency Anemia
Heart Disease Hepatic Encephalopathy
Iron Deficiency Anemia Neutropenia
Portal Hypertension Primary Thrombocytopenia

Graphical network of the top 20 diseases related to Hypersplenism:



Diseases related to Hypersplenism

Symptoms & Phenotypes for Hypersplenism

MGI Mouse Phenotypes related to Hypersplenism:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.41 ALB CD4 CSF2 CSF3 EGF EPO
2 hematopoietic system MP:0005397 10.4 CD4 CSF2 CSF3 EPO F2 FOXP3
3 homeostasis/metabolism MP:0005376 10.35 ALB CD4 CSF2 EPO F2 FOXP3
4 cardiovascular system MP:0005385 10.34 ALB CSF2 EPO F2 FOXP3 IFNG
5 cellular MP:0005384 10.33 ALB CD4 CSF2 EPO F2 FOXP3
6 growth/size/body region MP:0005378 10.32 BMP6 CD4 CSF2 EGF F2 FOXP3
7 endocrine/exocrine gland MP:0005379 10.26 ALB CD4 CSF2 EGF FOXP3 IFNG
8 digestive/alimentary MP:0005381 10.24 ALB CD4 EGF F2 FOXP3 IFNG
9 integument MP:0010771 10.21 CD4 CSF2 CSF3 EGF EPO F2
10 mortality/aging MP:0010768 10.21 ALB CD4 CSF2 EPO F2 FOXP3
11 liver/biliary system MP:0005370 10.1 ALB EPO FOXP3 IFNG IL4 LTA
12 normal MP:0002873 10.1 ALB CD4 EGF EPO F2 FOXP3
13 renal/urinary system MP:0005367 9.86 ALB CSF2 CSF3 FOXP3 IFNG IL4
14 respiratory system MP:0005388 9.85 CSF2 EPO F2 FOXP3 IFNG IL2RA
15 skeleton MP:0005390 9.7 BMP6 CSF2 EPO F2 GPT IFNG
16 vision/eye MP:0005391 9.32 EGF FOXP3 IFNG IL2RA IL4 LTA

Drugs & Therapeutics for Hypersplenism

Drugs for Hypersplenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
4
Warfarin Approved Phase 4 81-81-2 6691 54678486
5
Dalteparin Approved Phase 4 9005-49-6
6
Nadroparin Approved, Investigational Phase 4
7
Dipyridamole Approved Phase 4 58-32-2 3108
8
tannic acid Approved Phase 4 1401-55-4
9
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
12 Liver Extracts Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antibiotics, Antitubercular Phase 4
15 Antitubercular Agents Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Fibrinolytic Agents Phase 4
19 Anticoagulants Phase 4
20 Cyclooxygenase Inhibitors Phase 4
21 Heparin, Low-Molecular-Weight Phase 4
22 Platelet Aggregation Inhibitors Phase 4
23 Analgesics Phase 4
24 Antipyretics Phase 4
25 Vasodilator Agents Phase 4
26 Calcium, Dietary Phase 4
27 calcium heparin Phase 4
28 Anti-Inflammatory Agents, Non-Steroidal Phase 4
29
Calcium Nutraceutical Phase 4 7440-70-2 271
30
Epirubicin Approved Phase 1, Phase 2 56420-45-2 41867
31
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
32
Valproic acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
33
Lenalidomide Approved Phase 2 191732-72-6 216326
34
Melphalan Approved Phase 2 148-82-3 460612 4053
35
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
36
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
37 Neurotransmitter Agents Phase 1, Phase 2
38 Psychotropic Drugs Phase 1, Phase 2
39 Anticonvulsants Phase 1, Phase 2
40 Alkylating Agents Phase 2
41 Angiogenesis Inhibitors Phase 2
42 Protein Kinase Inhibitors Phase 2
43 Antimetabolites Phase 2
44
Gemcitabine Approved 95058-81-4 60750
45
Carboplatin Approved 41575-94-4 10339178 38904 498142
46
Oprelvekin Approved, Investigational 145941-26-0
47
Cisplatin Approved 15663-27-1 2767 441203 84093
48
Fluorouracil Approved 51-21-8 3385
49 Ethiodized oil Approved, Investigational 8008-53-5
50
Rivaroxaban Approved 366789-02-8

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Comparison Of Efficacy Of Two Immunosuppressive Protocols Including Tacrolimus With Or Without Mycophenolate Mofetil In Pediatric Liver Transplantation Aimed In Early Termination Of Steroid Therapy Completed NCT00195988 Phase 4 tacrolimus, steroids, mycophenolate mofetil
2 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Recruiting NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
3 Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study Unknown status NCT01560845 Phase 2, Phase 3
4 A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients. Unknown status NCT01936064 Phase 1, Phase 2 Placebo + Cyclophosphamide - Epirubicin 6
5 An Open Label Multicenter Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 in Adult Subjects With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Who Previously Received Treatment in Study LAL-CL01 Completed NCT01488097 Phase 2 sebelipase alfa
6 An Open-Label Multicenter Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Participants With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency Completed NCT01307098 Phase 1, Phase 2 Sebelipase alfa 0.35 mg/kg;Sebelipase alfa 1 mg/kg;Sebelipase alfa 3 mg/kg
7 Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
8 Revlimid®, and Metronomic Melphalan in the Management of Higher Risk Myelodysplastic Syndromes (MDS) and CMML: A Phase 2 Study" Completed NCT00744536 Phase 2 Lenalidomide and melphalan
9 Phase 1 Clinical Trial Using Mesenchymal Stem Cell and Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in End-stage Liver Disease Not yet recruiting NCT03460795 Phase 1, Phase 2
10 A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE Terminated NCT01539018 Phase 2 Sorafenib;sorafenib plus tegafur-uracil
11 Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy Unknown status NCT03269877
12 Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
13 Multicentric Retrospective Case Control Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
14 Management of Childhood Pancytopenia in Heamatology Unit in Assiut University Hospital Unknown status NCT03521947
15 The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy Unknown status NCT02344979
16 Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital Unknown status NCT03533322
17 A Randomized Controlled Trial of Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection Completed NCT00825669 TACE
18 The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications. Completed NCT00971698
19 Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis Completed NCT03201367 Rivaroxaban
20 The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension Recruiting NCT02778425
21 Differential Diagnostic of ITP and MDS: a Prospective Study by Next‐Generation Flow Cytometry and Cytomorphological Approaches Recruiting NCT03469661
22 HVPG-guided Laparoscopic Versus Endoscopic Therapy for Variceal Rebleeding in Portal Hypertension: A Multicenter Randomized Controlled Trial (CHESS1803) Recruiting NCT03783065 Propranolol
23 Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy Not yet recruiting NCT04113915 triple therapy;Steroids
24 Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder Terminated NCT00722254

Search NIH Clinical Center for Hypersplenism

Cochrane evidence based reviews: hypersplenism

Genetic Tests for Hypersplenism

Anatomical Context for Hypersplenism

MalaCards organs/tissues related to Hypersplenism:

40
Liver, Spleen, Bone, Bone Marrow, Kidney, T Cells, Myeloid

Publications for Hypersplenism

Articles related to Hypersplenism:

(show top 50) (show all 2084)
# Title Authors PMID Year
1
Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. 61 54
16215425 2005
2
Platelet count increase following phlebotomy in iron overloaded patients with liver cirrhosis. 61 54
12911944 2003
3
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. 61 54
12753144 2003
4
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. 61 54
12399221 2002
5
Role of plasma thrombopoietin level in thrombocytopenia of postoperative biliary atresia patients. 54 61
12149701 2002
6
Thrombocytopenia associated with liver cirrhosis and hepatitis C viral infection: role of thrombopoietin. 61 54
11100362 2000
7
Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. 61 54
11787473 2000
8
Laparoscopic cholecystectomy for cholelithiasis in patients with liver cirrhosis. 54 61
18493357 1995
9
Adverse Events Related to Partial Splenic Embolization for the Treatment of Hypersplenism: A Systematic Review. 61
32014400 2020
10
Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: a safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism. 61
31116622 2020
11
Portal vein thrombosis in Fontan-associated liver disease. 61
32406357 2020
12
Patterns of splenic arterial enhancement on computed tomography scan are related to portal venous hypertension. 61
31490421 2020
13
Successful Simultaneous Anatomic Subtotal Splenectomy During Pediatric Living-Donor Liver Transplantation: A Case Report. 61
32414607 2020
14
Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. 61
31471193 2020
15
Sickle cell disease and malaria: decreased exposure and asplenia can modulate the risk from Plasmodium falciparum. 61
32334583 2020
16
Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective. 61
32365650 2020
17
Clue to the cause of portal hypertension: Look at the raindrops. 61
32280785 2020
18
Significance of Amylase Monitoring in Peritoneal Drainage Fluid after Splenectomy: A Clinical Analysis of Splenectomy in 167 Patients with Hepatolenticular Degeneration. 61
32391757 2020
19
Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. 61
32314004 2020
20
Thromboelastography Detects Possible Coagulation Disturbance in Pediatric Patients with Portal Cavernoma. 61
32355473 2020
21
[Quantitative assessment of hepatic and splenic blood flow status in patients with hypersplenism of different degrees based on multi-slice spiral CT whole-liver perfusion imaging]. 61
32403885 2020
22
Interventions for preventing and managing advanced liver disease in cystic fibrosis. 61
32227478 2020
23
A Comparison of Splenic Pathologic Change and Immune Function in HBV-Related Portal Hypertension and Chinese Budd-Chiari Syndrome Patients with Hypersplenism. 61
32101101 2020
24
Concomitant Existence of Paroxysmal Nocturnal Hemoglobinuria in a Patient with Hb E (HBB: c.79G>A) Trait. 61
32354277 2020
25
Progressive Splenomegaly and Hypersplenism: An Unusual Case of Splenic Vein Stenosis with Histologic Findings of Hepatoportal Sclerosis. 61
31870607 2020
26
[Clinical efficacy of partial splenic arterial embolization in treatment of hypersplenism in patients with HBV-related cirrhosis]. 61
32306663 2020
27
Combined Laparoscopic Splenectomy and Esophagogastric Devascularization versus Open Splenectomy and Esophagogastric Devascularization for Portal Hypertension due to Liver Cirrhosis. 61
32166673 2020
28
Splenic serum from portal hypertensive patients enhances liver stem cell proliferation and self-renewal via the IGF-II/ERK signaling pathway. 61
31495600 2020
29
FDG-PET/CT Demonstrates Splenic Angiosarcoma Bone Marrow Metastasis. 61
31306197 2020
30
Rapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection. 61
31496023 2020
31
Atraumatic splenic rupture was attributed to intra-cystic haemorrhage and hypersplenism in a patient with cirrhosis and portal hypertension: A case report. 61
32047630 2020
32
Severe Complications After Splenic Artery Embolization for Portal Hypertension Due to Hepatic Cirrhosis. 61
32110126 2020
33
Comparison of early postoperative results between robot-assisted and laparoscopic splenectomy for non-traumatic splenic diseases rather than portal hypertensive hypersplenism-a meta-analysis. 61
31350089 2020
34
Isolated Splenic Lymphangiomas Presenting in an Infant with Isolated Anaemia. 61
32328111 2020
35
Recurrent kala-azar: report of two cured cases after total splenectomy. 61
32491143 2020
36
Effects of laparoscopic splenectomy and azygoportal disconnection on liver synthesis function and cirrhosis: a 2-year prospective study. 61
31820157 2019
37
Distal Splenorenal Shunt (DSRS) in Children with Extrahepatic Portal Hypertension. 61
31839103 2019
38
Investigation into imbalance of Th1/Th2 cells in cirrhotic, hypersplenic rats. 61
31852338 2019
39
Improvement of human platelet aggregation post-splenectomy with paraesophagogastric devascularization in chronic hepatitis B patients with cirrhotic hypersplenism. 61
31851564 2019
40
Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report. 61
31738743 2019
41
Impact of imbalanced graft-to-spleen volume ratio on outcomes following living donor liver transplantation in an era when simultaneous splenectomy is not typically indicated. 61
30830721 2019
42
Abnormal glucose metabolism in patients with Fontan circulation: Unique characteristics and associations with Fontan pathophysiology. 61
31425899 2019
43
Emergency or urgent splenectomy in children for non-traumatic reasons. 61
31312939 2019
44
Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients. 61
31273428 2019
45
Clinical Characteristics and Risk Factors for Sinistral Portal Hypertension Associated with Moderate and Severe Acute Pancreatitis: A Seven-Year Single-Center Retrospective Study. 61
31400275 2019
46
The Effects of Liver Transplantation in Children With Niemann-Pick Disease Type B. 61
30912297 2019
47
Etiology, presenting features and outcome of children with non-cirrhotic portal vein thrombosis: A multicentre national study. 61
30928422 2019
48
Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. 61
30462857 2019
49
From sadness to stiffness: the spleen's progress. 61
31152307 2019
50
Graft Hepatic Artery Rupture Due to Carbapenem-Resistant Klebsiella pneumoniae Infection After Liver Transplant. 61
31424357 2019

Variations for Hypersplenism

Expression for Hypersplenism

Search GEO for disease gene expression data for Hypersplenism.

Pathways for Hypersplenism

Pathways related to Hypersplenism according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TLR4 REL PIK3R1 LTA IL7R IL4
2
Show member pathways
13.85 THPO PIK3R1 LTA IL7R IL4 IL2RA
3
Show member pathways
13.51 THPO PIK3R1 LTA IL7R IL4 IL2RA
4
Show member pathways
13.44 TLR4 THPO PIK3R1 LTA IL7R IL4
5
Show member pathways
13.38 PIK3R1 LTA IL7R IL4 IL2RA IFNG
6
Show member pathways
13.36 THPO SERPINC1 PIK3R1 IL2RA F2 EGF
7
Show member pathways
13.33 TLR4 THPO PIK3R1 LTA IL7R IL4
8
Show member pathways
13.26 THPO PIK3R1 LTA IL7R IL4 IL2RA
9
Show member pathways
13.09 THPO PIK3R1 IL4 IL2RA F2 EGF
10
Show member pathways
13.04 TLR4 PIK3R1 IL7R IL4 IL2RA EPO
11
Show member pathways
12.9 LTA IL4 IL2RA IFNG FOXP3 CD4
12 12.85 PIK3R1 IL7R IL4 IL2RA IFNG F2
13
Show member pathways
12.82 THPO PIK3R1 LTA IL7R IL4 IL2RA
14
Show member pathways
12.74 TLR4 THPO REL PIK3R1 LTA EGF
15
Show member pathways
12.7 REL PIK3R1 LTA IFNG EGF CD4
16
Show member pathways
12.68 REL PIK3R1 IL4 IL2RA IFNG CD4
17
Show member pathways
12.64 TLR4 IL4 IL2RA IFNG FOXP3 CD4
18
Show member pathways
12.63 REL PIK3R1 IFNG F2 CD4
19 12.6 REL IL4 IL2RA IFNG FOXP3
20
Show member pathways
12.58 TLR4 REL PIK3R1 IL4 IFNG EGF
21 12.39 PIK3R1 LTA IL2RA CSF2 CD4
22
Show member pathways
12.38 REL IL4 IFNG CSF3 CSF2
23
Show member pathways
12.36 IL4 IFNG F2 ALB
24
Show member pathways
12.3 THPO LTA IL4 IL2RA IFNG BMP6
25
Show member pathways
12.25 THPO PIK3R1 IL7R IL4 IL2RA IFNG
26 12.23 TLR4 PIK3R1 IFNG EGF
27
Show member pathways
12.22 TLR4 REL IL4 IFNG
28
Show member pathways
12.16 PIK3R1 IL7R IL4 IL2RA
29
Show member pathways
12.06 REL IL4 IL2RA IFNG CD4
30 12.03 TLR4 PIK3R1 IFNG EPO EGF
31
Show member pathways
12 TLR4 LTA IFNG CD4
32 11.98 TLR4 PIK3R1 IFNG CSF2
33
Show member pathways
11.92 TLR4 IL4 IFNG CD4
34
Show member pathways
11.92 TLR4 REL FOXP3 CSF3 CSF2
35
Show member pathways
11.82 IL4 IL2RA IFNG FOXP3 CSF2
36 11.81 IL4 IFNG CSF2
37 11.81 IL7R IFNG CSF2 CD4
38 11.75 LTA IL7R IL4 IL2RA IFNG CD4
39
Show member pathways
11.73 PIK3R1 LTA IL4 IL2RA FOXP3
40 11.71 IL4 EGF CSF3 CSF2
41
Show member pathways
11.7 REL IFNG CSF2
42 11.69 PIK3R1 LTA IL4
43 11.62 TLR4 REL LTA
44
Show member pathways
11.6 REL LTA IFNG
45 11.59 TLR4 IFNG CSF3
46 11.58 IL4 CSF3 CSF2
47 11.56 TLR4 PIK3R1 IFNG
48 11.56 EPO CSF3 CSF2
49 11.55 THPO IL7R IL4 IL2RA EPO CSF3
50 11.54 IL4 IL2RA IFNG FOXP3 CD4

GO Terms for Hypersplenism

Cellular components related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 THPO SERPINC1 LTA IL7R IL4 IFNG
2 external side of plasma membrane GO:0009897 9.55 TLR4 IL7R IL2RA F2 CD4
3 extracellular space GO:0005615 9.44 THPO SERPINC1 LTA IL4 IFNG GPT
4 clathrin-coated vesicle membrane GO:0030665 9.43 IL7R EGF CD4

Biological processes related to Hypersplenism according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.22 TLR4 THPO PIK3R1 LTA IL7R IL4
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 TLR4 REL PIK3R1 IL4 FOXP3 CSF3
3 positive regulation of transcription, DNA-templated GO:0045893 10.04 REL IL4 FOXP3 EPO EGF CD4
4 cell surface receptor signaling pathway GO:0007166 9.95 IL7R IL2RA IFNG F2 CD4
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 TLR4 THPO EPO CD4
6 positive regulation of protein phosphorylation GO:0001934 9.92 THPO IFNG F2 CD4
7 positive regulation of protein kinase B signaling GO:0051897 9.91 THPO PIK3R1 EGF CSF3
8 response to nutrient GO:0007584 9.83 SERPINC1 LTA EPO
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 EGF CSF3 CD4 BMP6
10 negative regulation of neuron death GO:1901215 9.8 REL EPO CSF3
11 positive regulation of T cell proliferation GO:0042102 9.8 IL4 IL2RA CD4
12 cytokine-mediated signaling pathway GO:0019221 9.8 PIK3R1 IL4 IL2RA CSF3 CSF2 CD4
13 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.78 PIK3R1 F2 EPO CSF3
14 T cell activation GO:0042110 9.77 IL4 FOXP3 CD4
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 IL4 IFNG EPO CSF2
16 positive regulation of gene expression GO:0010628 9.76 TLR4 IL7R IL4 IFNG FOXP3 EGF
17 negative regulation of osteoclast differentiation GO:0045671 9.71 TLR4 PIK3R1 IL4
18 macrophage differentiation GO:0030225 9.67 IFNG CSF2 CD4
19 negative regulation of T-helper 17 cell differentiation GO:2000320 9.65 IL4 FOXP3
20 positive regulation of cell proliferation GO:0008284 9.65 THPO IL7R IL4 IFNG F2 EPO
21 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.64 CSF2 CD4
22 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2RA FOXP3
23 regulation of regulatory T cell differentiation GO:0045589 9.61 IL2RA IFNG FOXP3
24 positive regulation of cellular respiration GO:1901857 9.59 IL4 IFNG
25 neuroinflammatory response GO:0150076 9.58 IL4 IFNG
26 positive regulation of interleukin-23 production GO:0032747 9.58 IFNG CSF2
27 negative regulation of interleukin-17 production GO:0032700 9.58 TLR4 IFNG FOXP3
28 negative regulation of chronic inflammatory response GO:0002677 9.56 IL4 FOXP3
29 macrophage activation GO:0042116 9.54 TLR4 IL4 CSF2
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 TLR4 IL4 IFNG
31 immune response GO:0006955 9.32 TLR4 LTA IL7R IL4 IL2RA IFNG

Molecular functions related to Hypersplenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.55 TLR4 THPO LTA F2 CD4
2 growth factor activity GO:0008083 9.5 THPO IL4 F2 EGF CSF3 CSF2
3 cytokine activity GO:0005125 9.23 THPO LTA IL4 IFNG EPO CSF3

Sources for Hypersplenism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....